Brief Title: Paracervical Block for Postoperative Pain After Transcervical Procedures Under TIVA
EFFECTIVENESS OF PARACERVICAL BLOCK IN ADDITION TO STANDARD ANALGESIA FOR POSTOPERATIVE PAIN CONTROL FOLLOWING TRANSCERVICAL UTERINE PROCEDURES UNDER TIVA: A RANDOMIZED CONTROLLED TRIAL
Paracervical Block for Postoperative Pain After Transcervical Procedures Under TIVA
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
EFFECTIVENESS OF PARACERVICAL BLOCK IN ADDITION TO STANDARD ANALGESIA FOR POSTOPERATIVE PAIN CONTROL FOLLOWING TRANSCERVICAL UTERINE PROCEDURES UNDER TIVA: A RANDOMIZED CONTROLLED TRIAL
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Zeenat Usman, MS obstetrics and Gyanecology
- Phone Number: +923315333910
- Email: usmanbut2@gmail.com
Study Contact Backup
- Name: Quratulain Assosciate Professor, FCPS - Obstetrics and Gynaecol
- Phone Number: +92335587882
- Email: qurratulain_saeed@yahoo.com
Study Locations
-
-
Islamabad
-
Islamabad, Islamabad, Pakistan, 04485
- Pakistan Institute of Medical Sciences (PIMS)
-
Contact:
- Zeenat Usman, MS Obstetrics and gyanecology
- Phone Number: +923315333910
- Email: qurratulain_saeed@yahoo.com
-
Contact:
- Quratulain Associate Professor, FCPS - Obstetrics and Gynaecol
- Phone Number: +92335587882
- Email: qurratulain_saeed@yahoo.com
-
Principal Investigator:
- Zeenat Usman, MS obstetrics and gyane
-
Sub-Investigator:
- Quratulain Saeed, FCPS - Obstetrics and Gynaecol
-
Sub-Investigator:
- Tooba Batool
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women aged 18 years or older.
- Women scheduled to undergo an eligible transcervical uterine procedure under total intravenous anaesthesia (TIVA).
- Women with stable haemodynamic condition before surgery.
Exclusion Criteria:
- Known allergy or hypersensitivity to lidocaine or other planned local anaesthetic.
- Significant hepatic disease affecting local anaesthetic metabolism.
- Chronic opioid use or chronic pain requiring regular analgesic therapy.
- Major intraoperative complication requiring deviation from the standardized anaesthetic or surgical protocol.
- Patients requiring emergency surgery where informed consent or standardized study procedures cannot safely be completed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Paracervical Block Plus Standard Analgesia
Participants will receive a standardized paracervical block using lidocaine in addition to standard total intravenous anesthesia (TIVA) and perioperative analgesia for eligible transcervical uterine procedures. Postoperative pain scores and analgesic requirements will be assessed and compared with the control group. |
A standardized paracervical block will be administered after induction of total intravenous anesthesia (TIVA) and before uterine manipulation. The technique will use 2% lidocaine without adrenaline, with 1 mL injected at each of four cervical positions (2, 4, 8, and 10 o'clock), for a total volume of 4 mL (80 mg lidocaine). Aspiration will be performed before and during injection to reduce the risk of intravascular administration. The block will be given in addition to standard TIVA and perioperative analgesia for eligible transcervical uterine procedures. |
|
No Intervention: Standard Analgesia Alone
Participants will receive standard total intravenous anesthesia (TIVA) and perioperative analgesia for eligible transcervical uterine procedures without a paracervical block. Postoperative pain scores and analgesic requirements will be assessed and compared with the intervention group. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative Pain Score (0-10 Visual Analogue Scale [VAS] Score)
Time Frame: From arrival in the recovery area (when awake and able to communicate) to 4 hours post-procedure, assessed at recovery arrival, 30 minutes, 1 hour, 2 hours, and 4 hours where feasible.
|
Postoperative pain intensity will be measured using a 0-10 Visual Analogue Scale (VAS), with 0 representing no pain and 10 representing the worst imaginable pain. The VAS score will be recorded for each participant at recovery room arrival (when awake and able to communicate), 30 minutes, 1 hour, 2 hours, and 4 hours after the procedure, where feasible. The mean or median postoperative pain scores will be compared between participants receiving paracervical block plus standard analgesia and those receiving standard analgesia alone. |
From arrival in the recovery area (when awake and able to communicate) to 4 hours post-procedure, assessed at recovery arrival, 30 minutes, 1 hour, 2 hours, and 4 hours where feasible.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Participants Requiring Rescue Analgesia (%)
Time Frame: From completion of the procedure until 4 hours post-procedure.
|
The proportion of participants requiring additional rescue analgesia for postoperative pain despite receiving standard perioperative analgesia will be recorded. Rescue analgesia requirement will be assessed as a binary outcome (Yes/No) using the study Case Report Form (CRF). The percentage of participants requiring rescue analgesia will be compared between the intervention and control groups.Control group is the one receiving standard analgesia that is only TIVA and case group is standard analgesia that is TIVA and paracervical block group |
From completion of the procedure until 4 hours post-procedure.
|
|
Time to First Rescue Analgesia (Minutes)
Time Frame: From completion of the procedure until 4 hours post-procedure
|
Time to first rescue analgesia will be measured in minutes from completion of the transcervical uterine procedure to administration of the first rescue analgesic. The time of administration will be documented using the medication administration record and structured Case Report Form (CRF), and compared between the two study groups. |
From completion of the procedure until 4 hours post-procedure
|
|
Total Postoperative Rescue Analgesic Requirement (Drug-Specific Dose)
Time Frame: From completion of the procedure until 4 hours post-procedure.
|
The total dose of additional rescue analgesic medication administered to each participant for postoperative pain will be recorded using the medication administration record and structured Case Report Form (CRF). The drug name, individual dose and total dose administered during the postoperative observation period will be documented and compared between the two study groups. Results will be expressed in the appropriate drug-specific dose units (e.g., milligrams). |
From completion of the procedure until 4 hours post-procedure.
|
|
Patient Satisfaction Score with Postoperative Pain Management (5-Point Likert Scale)
Time Frame: At the end of the postoperative recovery observation period, up to 4 hours after the procedure.
|
Participant satisfaction with postoperative pain management will be assessed using a predefined 5-point Likert scale recorded on the structured Case Report Form (CRF). The scale ranges from 1 (very dissatisfied), 2 (dissatisfied), 3 (neutral), 4 (satisfied), to 5 (very satisfied). Individual satisfaction scores will be recorded and compared between the two study groups. |
At the end of the postoperative recovery observation period, up to 4 hours after the procedure.
|
|
Time to First Mobilization (Minutes)
Time Frame: From completion of the procedure until first mobilization or discharge from the recovery area, whichever occurs first, within 4 hours post-procedure.
|
Time to first mobilization will be measured in minutes from completion of the transcervical uterine procedure to the participant's first mobilization. The time will be recorded using the structured Case Report Form (CRF) and compared between participants receiving paracervical block plus standard analgesia and those receiving standard analgesia alone. |
From completion of the procedure until first mobilization or discharge from the recovery area, whichever occurs first, within 4 hours post-procedure.
|
|
Incidence of Postoperative Nausea and Vomiting (Number and Percentage of Participants)
Time Frame: From arrival in the recovery area until 4 hours after completion of the procedure.
|
The incidence of postoperative nausea and vomiting will be assessed by recording the presence or absence of nausea and vomiting (Yes/No) using the structured Case Report Form (CRF). The requirement for rescue antiemetic medication will also be documented as Yes or No. Results will be expressed as the number and percentage of participants experiencing nausea and vomiting in each study group. |
From arrival in the recovery area until 4 hours after completion of the procedure.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Zeenat Usman, MS obstetrics and Gyanecology, SZABMU,PIMS
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Postoperative Complications
- Pathologic Processes
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pain, Postoperative
- Organic Chemicals
- Anilides
- Amides
- Aniline Compounds
- Amines
- Acetanilides
- Anesthesia and Analgesia
- Anesthesia
- Lidocaine
- Anesthesia, Obstetrical
Other Study ID Numbers
Other Study ID Numbers
- F-5-2/2024(ERRC)30th-PIMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data collected during this study will not be shared publicly or made available to external researchers. Data will be used by the study investigators for the purposes of the approved research. Participant confidentiality will be maintained in accordance with institutional ethical requirements.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.